Recordati Quote - REC

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

51.80

Bid

51.75

Offer

51.80

Volume

29,907

51.70 Day's Range 52.30

46.34 52 Week Range 60.50

Market Cap

10.638B

Previous Close

52.45

Open

52.05

Last Trade

261

51.8

Last Trade Time

19:52:01

Financial Volume

VWAP

Average Volume (3m)

432,028

Shares Outstanding

205,358,104

Dividend Yield

2.32%

PE Ratio

27.63

Earnings Per Share (EPS)

2.03

Revenue

2.33B

Net Profit

416.51M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.recordati.it

Headquarters

Milan, Lombardy, Ita

Founded

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 52.45 €. Over the last year, Recordati shares have traded in a share price range of 46.34 € to 60.50 €.

Recordati currently has 205,358,104 shares in issue. The market capitalisation of Recordati is 10.77 € billion. Recordati has a price to earnings ratio (PE ratio) of 27.63.

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA®...

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2...

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND €...

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 –...

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

The LINC 4 study demonstrated superiority of Isturisa® (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.5	2.98210735586	50.3	52.65	49.98	317725	51.635179	DE
4	2.78	5.67115463076	49.02	54.3	48.64	387517	51.67484658	DE
12	-2	-3.71747211896	53.8	55.05	46.34	432028	51.97835035	DE
26	0.95	1.86823992134	50.85	60.5	46.34	377872	53.18101623	DE
52	3.26	6.71611042439	48.54	60.5	46.34	304957	52.14308396	DE
156	9.24	21.7105263158	42.56	60.5	34.52	253117	47.02519412	DE
260	10.62	25.789218067	41.18	60.5	34.52	272240	46.92641153	DE

REC - Frequently Asked Questions (FAQ)

What is the current Recordati share price?

The current share price of Recordati is 51.80 €

How many Recordati shares are in issue?

Recordati has 205,358,104 shares in issue

What is the market cap of Recordati?

The market capitalisation of Recordati is EUR 10.77B

What is the 1 year trading range for Recordati share price?

Recordati has traded in the range of 46.34 € to 60.50 € during the past year

What is the PE ratio of Recordati?

The price to earnings ratio of Recordati is 27.63

What is the cash to sales ratio of Recordati?

The cash to sales ratio of Recordati is 4.95

What is the reporting currency for Recordati?

Recordati reports financial results in EUR

What is the latest annual turnover for Recordati?

The latest annual turnover of Recordati is EUR 2.33B

What is the latest annual profit for Recordati?

The latest annual profit of Recordati is EUR 416.51M

What is the registered address of Recordati?

The registered address for Recordati is VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

What is the Recordati website address?

The website address for Recordati is www.recordati.it

Which industry sector does Recordati operate in?

Recordati operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NSPNeosperience Spa	0.488 € (10.41%)	42k
AGAINCloudia Research	1.68 € (9.80%)	126k
1SNOWSnowflake Inc	176.78 € (9.46%)	4
CYBCyberoo SpA	1.60 € (8.84%)	110.83k
FPEFope	34.60 € (6.79%)	1.5k
WBELLBellini Nauttica Spa	0.0008 € (-80.95%)	20k
WELESEles Spa	0.096 € (-26.15%)	40k
VNEVNE SpA	1.75 € (-16.67%)	89.95k
1FNTNFreenet AG	30.38 € (-14.47%)	47
MTVMondo TV Spa	0.0476 € (-13.45%)	3.36M
TITTelecom Italia SpA	0.3862 € (-2.28%)	101.65M
FDAFidia	0.0053 € (0.00%)	41.48M
ISPIntesa Sanpaolo Spa	4.891 € (-1.21%)	17.08M
SPMSaipem Spa	2.077 € (-1.05%)	10.81M
ENELEnel Spa	8.106 € (0.31%)	10.42M

nssrr5 1 minute ago

The markets will see new lows after this way over bought bear market rally.

TSLA

RickNagra 3 minutes ago

I suspect we will be on CNBC and FOX this morning before the opening ding ding ding. There will be some serious institutional buying pressure today. Volume should be 100 million minimum I would think.

FNMA

Robert from yahoo bd 3 minutes ago

'In a message posted on Truth Social Wednesday night, Trump said “I am giving serious consideration to bringing Fannie Mae and Freddie Mac public.”

He added that he would be meeting with Pulte, Treasury Secretary Scott Bessent and Commerce Secretary Howard Lutnick and “making a decisi

FNMA

Eurotraders987 5 minutes ago

I watched the podcast with Tom the CEO about their utilization of AI, its seriously good and has value. Maybe the world hast woken up to this stock last. I was bidding .28 for 100.000 shares the past few days, didnt get 1 lousy share. Ill try again today maybe a little higher.

BBLR

RickNagra 6 minutes ago

Currently up 30.12% in Stuttgardt but I believe we will go higher here in the USA. Germans drink too much beer anyways which potentially can impair their thinking LOL.

FNMA

newmedman 10 minutes ago

I always loved my teachers...

https://bsky.app/profile/jessigrace.bsky.social/post/3lppu3ho7g22y

knrorrel 12 minutes ago

MLGO https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176224636

MLGO

knrorrel 13 minutes ago

MLGO which looks fantastic and was recently at over $20 and when the $2 will be passed more and more people will come in and jump in and it will be a self-running thing like KDLY, imo

KDLY MLGO

Cameo Brien 13 minutes ago

Loaded

IQST

knrorrel 13 minutes ago

MLGO which looks fantastic and was recently at over $20 and when the $2 will be passed more and more people will come in and jump in and it will be a self-running thing like KDLY, imo

KDLY MLGO

Dcab 14 minutes ago

https://www.paypilot.org/

BELR

Uncle Monkey 16 minutes ago

.30s today????

CBRF

ksquared 17 minutes ago

Good grief. What will they think of next?
Good Morning, Larry.
Hope the 12 bales of illegal alien invaders get sent right back where they came from.

knrorrel 19 minutes ago

$MLGO - Mkt Cap 37.991M - cash 217M
67% shares holder is $WIMI

mircro freefloat

short squeeze reloaded
all only imho

MLGO WIMI

willpellel 21 minutes ago

Well. I'm sitting on 400 million so yes, when it moves, we have the strength cause a run.

PSRU

scotty3371 22 minutes ago

In the UK, under the Human Tissue Authority (HTA) regulations, the individual primarily responsible for the overall quality and safety of human tissues and cells for human application is the Designated Individual (DI). While the DI has the ultimate responsibility, they can delegate tasks to other su

NWBO

knrorrel 23 minutes ago

$MLGO - Mkt Cap 37.991M - cash 217M
67% shares holder is $WIMI

mircro freefloat

short squeeze reloaded
all only imho

MLGO WIMI

chxal 26 minutes ago

Thank you Captain B, I see it was as high as 8.60 Euros in German market, we are in Greece now (Mykonos) and the Euro is at 1.13 so this effectively makes the trades at
8.60 = $9.72 can't wait to see the US open! Tks again - Chxal

FNMA

sctts 28 minutes ago

$$$ Today is the Day $$$$

$$$$ $FRX $$$

FRX

fuagf 33 minutes ago

LOL Hope he either finds a use for it, or gives it to a friend at a very cheap price.

fuagf 35 minutes ago

Yep. Those hard core MAGAs are as uncaring about American
democracy and of their fellow citizens welfare as Trump is.

sony12 35 minutes ago

IMO COMPANY WILL COME BACK IF MR KLUG GETS THE COURTS ON HIS SIDE IMO

EternalPatience 37 minutes ago

I hear you and i was just joking on professional etiquette or moral responsibility and fully committed to do that..

But please remember, corporate america doesnt care about all that and what you have given to them, particularly in today's day and age of firing by the thousands a day

FNMA

lakers17 38 minutes ago

XMR (Monero) is a weird one. Wanted more but it has run from $200 to $400 in the last month or so. It's a more private BTC type token. Weird as Coinbase and many other central exchange won't carry it.

LoveThemStocks 39 minutes ago

Nvidia Stock Rises. Why This Analyst’s Shrugging Off China Chip Restrictions Impact https://finance.yahoo.com/m/a04ad7a0-7d2b-3f0c-9d4e-9b23d3527da4/nvidia-stock-rises-why-this.html

NVDA

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Recordati SpA (REC)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Recordati SpA

Ask ADVFN Intelligence (AI)

REC Latest News

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Recordati SpA (REC) Share Price

Recordati SpA (REC)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Recordati SpA

Ask ADVFN Intelligence (AI)

REC Latest News

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Sign in

Go Ad-Free